Skip to main content
women seating in front of microscope with all protecting gear

Interventional Cardiology Therapies

Our focus

Minimally invasive technologies to improve the lives of patients living with heart and vascular conditions.

Jim’s story

We’re committed to advancing interventional cardiology therapies through less invasive technologies that improve outcomes, deliver care to more patients, reduce costs, and help millions live healthier lives.

Delivering meaningful innovation

Modern approach to percutaneous coronary intervention (PCI).

A comprehensive portfolio of PCI devices and training designed to help interventional cardiologists provide patients with complex coronary artery disease the best possible treatment and quality of life.

Peace of mind.

The SENTINEL™ Cerebral Protection System (CPS) is the first and only commercially available device in the U.S. offering protected transcatheter aortic valve replacement (TAVR) – proven embolic protection against the risk of TAVR-related stroke.

Healing with confidence.

 Available in a portfolio with distinct options to treat the unique needs of patients, the SYNERGY™ Bioabsorbable Polymer Stent is intentionally designed with thin struts and a fast-absorbing bioabsorbable polymer coating, which enable rapid healing and shortened dual-antiplatelet therapy.  

Designed to optimize TAVR.

The ACURATE neo2™ Aortic Valve System* is a self-expanding, supra-annular valve designed to provide effective sealing, placement accuracy, predictable release, and expanded patient access for patients with aortic stenosis who are indicated for TAVR.

~200

lives impacted every hour by Boston Scientific Interventional Cardiology Therapies.1

> 60k

patients treated worldwide with the ACURATETM Aortic Valve System1 *

> 100k patients

treated worldwide with the AGENTTM Drug-Coated Balloon.1

>18.4 million

coronary drug eluting stent implants globally.1

>5.6 million

SYNERGY™ Bioabsorbable Polymer Stent implants.1

Conditions we treat

  • Cardiovascular Diseases
  • Coronary Artery Disease

~6M

patients undergo PCIs worldwide annually.2

1.8M

patients worldwide affected with calcium.2

4.5M

patients with aortic stenosis.3

3.5M

patients with moderate-severe mitral regurgitation.4

Solutions we offer

  • Transcatheter Aortic Valve Replacement (TAVR)
  • Cerebral Embolic Protection (CEP)
  • Drug-Eluting Technologies
  • Complex Percutaneous Coronary Intervention (PCI)
  • PCI Guidance
  •  Calcium Treatment

Product spotlights

SENTINEL Cerebral Protection System

AGENT™ Drug-Coated Balloon

The AGENT™ Drug-Coated Balloon is the first and only coronary drug-coated balloon approved for use in the U.S. Available in global markets since 2014, AGENT expands treatment options for patients with coronary artery disease who experience in-stent restenosis by delivering a targeted anti-stenotic drug dose without an extra layer of metal.

Learn more about the AGENT Drug-Coated Balloon
SENTINEL Cerebral Protection System

SENTINEL™ Cerebral Protection System (CPS)

The SENTINEL Cerebral Protection System offers protection from the risk of stroke during TAVR. It works by capturing embolic debris dislodged during TAVR before it can reach the brain. Clinical trials involving more than 5,000 patients patients have demonstrated that the SENTINEL device is safe and effective. This technology has been used to protect thousands of patients worldwide and is the most-studied embolic protection device in its field.5-7

Learn more about the SENTINEL CPS
SYNERGY BP Stent

SYNERGY™ Bioabsorbable Polymer Stent System

The SYNERGY BP Stent is a drug-eluting stent with a bioabsorbable polymer coating designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis, and late stent thrombosis.

The SYNERGY BP Stent provides synchronous drug elution and polymer absorption providing rapid healing and freedom from long-term polymer exposure. In more than 18,000 patients across nine studies, this technology demonstrated outstanding safety with consistently low stent thrombosis rates.8

Learn more about the SYNERGY BP Stent
ACURATE neo2 Aortic Valve System

ACURATE neo2™ Aortic Valve System*

The ACURATE neo2 Aortic Valve System is a TAVR technology indicated to restore function and normal blood flow through a severely narrowed valve in patients with aortic stenosis. The new platform is designed with several features to improve upon the clinical performance of the original ACURATE neo platform, including a new annular sealing technology that conforms to irregular, calcified anatomies and further minimizes paravalvular leakage to ensure the best patient outcomes. 

Learn more about the ACURATE neo2 Aortic Valve System
AVVIGO Guidance System II

AVVIGO™+ Multi-Modality Guidance System 

The AVVIGO™+ Multi-Modality Guidance System is a streamlined software and hardware platform that provides high-quality intravascular imaging (IVUS) and physiology experience. The new platform is designed with several features to enable faster, more efficient procedures for patients with coronary artery disease, including a machine learning algorithm to provide physicians with automated and precise vessel measurements.

Learn more about the AVVIGO+ Multi-Modality Guidance System

Sources

  1. Internal Boston Scientific data
  2. Internal BSC estimate
  3. https://pubmed.ncbi.nlm.nih.gov/29622096/
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974123/
  5. Van Mieghem N. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Erasmus Medical Center, presented at TVT 2018. 
  6. Seeger J. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, University of Ulm, presented at TVT 2018. 
  7. Chakravarty T. Snapshots from Real World High Volume Single Center Experiences with Sentinel Cerebral Embolic Protection During TAVR, Cedars Sinai Medical Center, presented at TVT 2018.
  8. SWEET Registry: Cook TCT 2015., Fribourg Experience: Arroyo CRT 2016. Belfast Experience: Noad TCT 2015., EVOLVE II: Kereiakes, et al. Circ Cardiovasc Interv. 2015;8:e002372.DOI:10.1161/CIRCINTERVENTIONS.114.002372.,EVOLVE FHU: Meredith et al. J Am Coll Cardiol. 2012;59(15):1362., EVOLVE II QCA: Meredith ACC 2015., SCAAR Registry: James TCT 2016 BIO-RESORT presented by Clemens von Birgelen, MD PhD, TCT 2016.

*Caution: In the EU, ACURATE neo2 is CE-marked. In the US, ACURATE neo2 is an Investigational Device, approved for Investigational Use only. Not available for sale. Federal law (U.S.) restricts these devices to sale by or on the order of a physician.